ESC Premium Access

Impact of polypharmacological strategy on mortality and morbidity in predominantly older HF population across different HF phenotype.

Presentation

About the speaker

Doctor Annamaria Iorio

Hospital and University of Trieste, Division of Cardiology, Trieste (Italy)
0 follower

49 more presentations in this session

Survival in HFpEF vs HFrEF patients after beta-blocker titration: new insights from the CIBIS-ELD trial

Speaker: Associate Professor H. Duengen (Berlin, DE)

Thumbnail

Dual V1a/V2 versus selective V2 vasopressin receptor blockade in a preclinical heart failure model: does it matter?

Speaker: Doctor T. Mondritzki (Wuppertal, DE)

Thumbnail

The use of Guideline recommended betablocker therapy in primary prevention ICD patients. Insight from Danish nationwide registries

Speaker: Doctor A. Huth Ruwald (Roskilde, DK)

Thumbnail

The effect of angiotensin II type 2 receptor agonist treatment on doxorubicin induced heart failure

Speaker: Associate Professor N. Ermis (Malatya, TR)

Thumbnail

Triiodo-L-thyronine promotes the therapeutic efficacy for myocardial infarction of bone marrow mesenchymal stem cells

Speaker: Professor S. Nie (Beijing, CN)

Thumbnail

Access the full session

Poster session 7 - Heart failure / Left ventricular dysfunction

Speakers: Doctor A. Iorio, Associate Professor H. Duengen, Doctor T. Mondritzki, Doctor A. Huth Ruwald, Associate Professor N. Ermis...
Thumbnail

About the event

Image

ESC CONGRESS 2016

27 August - 31 August 2016

Sessions Presentations

This platform is supported by

logo Novo Nordisk